09:36 AM EST, 02/20/2026 (MT Newswires) -- (Updates with stock price in the last paragraph and clarifies the first and third paragraphs)

Corcept Therapeutics ( CORT ) said Thursday the US Court of Appeals found that Teva Pharmaceuticals' (TEVA) marketing of a generic version of Korlym does not infringe on two of the company's patents.

The patents include methods of co-administering Korlym and other drugs, including drugs that are commonly prescribed to patients with Cushing's syndrome.

The ruling affirms a 2023 verdict by a federal district court, the company said.

The company is considering the "best way to pursue judicial review of this decision," said Corcept Chief Executive Joseph Belanoff.

"We are disappointed in the Court's ruling," he said. "The patents we asserted in this case cover methods of safely treating patients with Cushing's syndrome that physicians rely on every day.

CORT shares were down 2.7% recent trading. TEVA shares were 1.6% lower.

Price: 33.68, Change: -0.56, Percent Change: -1.64